July 21, 2022 Private equity gets serious about drug development Venture capital has the brains, private equity has the books – can they make lots of money?
October 28, 2020 Another complement factor enters the deal-making frame Sobi picking up rights to Apellis’s complement factor C3 inhibitor adds to earlier deals focused on C5, D and anti-FcRn antibodies.
